Oxford BioMedica PLC (OXBDF)

[marcusl2]

George, this is interesting; 5T4 oncofoetal antigen: an attractive target for immune intervention in ...
link.springer.com/article/10.1007/s00262-016-1917-3
Peter L. Stern; Richard HarropEmail author. Review. First Online: 18 ..... Unpublished data are provided by Oxford BioMedica (OXB). The table summarises the .

In addition, a chimeric antigen receptor T cell approach targeting 5T4 expressing tumour cells is in pre-clinical development. A key challenge will include how best to combine each 5T4 targeted immunotherapy with the most appropriate standard of care treatment (or adjunct therapy) to maximise the recovery of immune control and ultimately eliminate the tumour.
HTTP://link.springer.com/article/10.1007/s00262-016-1917-3

Carl June/Novartis, early next year they are using Crisp R to knock out the PD-1 before using CAR T.